Comment: Veliparib With Carboplatin And Paclitaxel In Advanced Gbrca-Positive Breast Cancers

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastati...

Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer

Targeted Oncology

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer

Nab-Paclitaxel as Neoajuvant Therapy for Breast Cancer

Veliparib misses PFS endpoint, advances to phase III trial

MDedge: news and insights for busy physicians

ASCO 2020 - Heather Han, MD - Abstract 1091

Moffitt Cancer Center

Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer

Combination Veliparib and Chemotherapy in Ovarian Cancer

Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian Cancers

Targeted Oncology

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in N...

Final Insight: PARPs and gBRCA in Breast Cancer

#chemo #chemotherapy Carboplatin and paclitaxel are chemotherapy agents that are used in combination

Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib

Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer

Targeted Oncology

Study of preoperative treatment with nab-paclitaxel and pembrolizumab in HR+ breast cancer

Dana-Farber Cancer Institute

Dr. Hope Rugo on the First-line Superiority of Paclitaxel for Advanced Breast Cancer

Updates in metastatic and early-stage breast cancer

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer